Novo Nordisk reports 10% profit increase for Q1 2017

Novo Nordisk has reported profit of €1.4 billion for the first quarter of 2017, which is increase of 10%.

During the first quarter of 2017 the company has received marketing authorisation from the European Commission as well as approvals in Norway, Iceland and Canada for its fast-acting insulin aspart, Fiasp. Additionaly, Novo Nordisk resubmitted the New Drug Application for fast-acting insulin aspart in the USA following the Complete Response Letter received in October 2016.

Also, in March, Novo Nordisk received positive opinion from the European Medicines Agency for the recommendation of a marketing authorisation for Refixia (nonacog beta pegol, N9-GP) for the treatment of haemophilia B.

In May, Novo Nordisk received approval from the EU commission for the label update of Tresiba based on data from the SWITCH trials, demonstrating a clinically relevant reduction in hypoglycaemia compared with insulin glargine U100.

Also, the company has appointed Lars Green as a new executive vice president and head of Business Services and Compliance effective 1 July 2017.

Lars Fruergaard Jørgensen, president and CEO: “With the performance in the first three months, we are well on track towards our targets for 2017. Sales were driven by our new, innovative products within diabetes and obesity care, and we are seeing the effects of our cost control initiatives, enabling us to invest in future growth opportunities.”